No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Axsome Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative treatments for central nervous system (CNS) disorders, primarily focusing on the United States market. Its pipeline includes AXS-05, a therapeutic candidate for major depressive disorder and treatment-resistant depression, which is also currently in Phase III clinical trials for Alzheimer's disease agitation and has completed Phase II studies for smoking cessation. The company is also advancing AXS-07, an experimental, rapidly absorbed, oral medication with a multi-mechanistic profile, which has successfully concluded two Phase III trials for the acute treatment of migraine. Another key asset is AXS-12, a selective and potent norepinephrine reuptake inhibitor, presently in Phase III development for narcolepsy. Furthermore, AXS-14, an investigational oral medicine, is undergoing Phase III trials for fibromyalgia. Axsome Therapeutics maintains a research collaboration with Duke University to further evaluate AXS-05 for smoking cessation. The company was founded in 2012 and is headquartered in New York, New York.
www.axsome.comNo one on the platform currently holds 0HKF.L.
No tracked institution reports a position in 0HKF.L as of their last filing.
No one on the platform has traded 0HKF.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 65.5% | |||||
| Profit Margin % | -28.7% | |||||
| Free Cash Flow Margin % | -14.7% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $966M | +52.0% | $-2.67 | $-3.01–$-2.26 | — | 1 |
| 2027 | $1.6B | +61.7% | $4.66 | $3.94–$5.25 | — | 1 |
| 2028 | $2.2B | +43.3% | $12.56 | $10.63–$14.16 | — | 1 |
| 2029 | $3.1B | +36.9% | $22.27 | $18.85–$25.10 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-10 | $-0.89 | $-0.99 | -11.0% |
| 2026-05-04 | $-0.84 | $-1.26 | -49.2% |
| 2026-02-23 | $-0.69 | $-0.56 | +19.3% |
| 2025-11-03 | $-0.86 | $-0.94 | -9.2% |
| 2025-08-04 | $-1.06 | $-0.97 | +8.1% |
| 2025-05-05 | $-1.35 | $-1.22 | +9.7% |
| 2025-02-18 | $-1.00 | $-1.54 | -53.8% |
| 2024-11-12 | $-1.38 |
| $-1.34 |
| +3.1% |
| +2.27% |
| $12.9B |
| — |
| 0JZ2.LMasimo Corporation | $179.96 | +0.01% | $9.5B | — |
| 0L3C.LHenry Schein, Inc. | $87.95 | +0.08% | $10.2B | — |
Source: Financial Modeling Prep · peers by sector/industry